论文部分内容阅读
目的:评价新型抗癫药物左乙拉西坦(Lev)作为添加治疗对难治性部分性癫患者生活质量的影响。方法:43例确诊有癫部分性发作的成年患者随机分为两组:Lev治疗组与安慰剂组,Lev治疗16周后比较两组的有效率和不良反应,并用QOLIE-31量表对两组癫患者进行生活质量评定,所有患者在转入Lev开放性治疗6个月后再次进行QOLIE评估。结果:16周治疗期末Lev组癫部分性发作的治疗有效率明显高于安慰剂组,两组不良反应的发生率相当;Lev组生活质量明显高于安慰剂组,两组患者转入开放性治疗6个月后,生活质量均显著改善。结论:Lev作为添加用药治疗成人难治性部分性癫发作,显著减少发作频率、安全耐受性较好,能够提高癫患者的生活质量。
OBJECTIVE: To evaluate the effect of levodocisol (Lev), a new antiepileptic drug, on the quality of life in patients with refractory partial epilepsy. Methods: Forty-three adult patients diagnosed as partial epileptic seizures were randomly divided into two groups: Lev group and placebo group. After 16 weeks of Lev treatment, the efficacy and adverse reactions of the two groups were compared. QOLIE-31 Quality of life was assessed in both groups of patients with epilepsy, and all patients were re-evaluated for QOLIE after 6 months of open Lev treatment. Results: The effective rate of partial epileptic seizures in Lev group was significantly higher than that in placebo group at the end of the 16-week treatment period, and the incidence of adverse reactions was similar in both groups. The quality of life in Lev group was significantly higher than that in placebo group, After six months of sexual treatment, the quality of life was significantly improved. Conclusion: Lev as an add-on therapy for refractory paroxysmal epileptic seizures in adults, significantly reduce the frequency of seizures, better safety tolerance, can improve the quality of life in patients with epilepsy.